Low-Dose radiation plus immunotherapy shows promise in rectal cancer trial

NCT ID NCT07448142

First seen Apr 18, 2026 · Last updated May 01, 2026 · Updated 1 time

Summary

This study tests whether a low dose of radiation, combined with an immunotherapy drug (pucotenlimab) and chemotherapy (CAPEOX), can shrink or eliminate locally advanced rectal cancer before surgery. About 50 adults with a specific type of rectal cancer (pMMR/MSS) will receive either 2 Gy or 5 Gy of radiation, followed by the drug combination. The goal is to see if this approach leads to a complete response, meaning no cancer is detectable after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dept. of Colorectal Surgery, Sun Yat-sen University Cancer Center. Yuexiu District, Dongfeng East Road 651

    RECRUITING

    Guangzhou, Guanggong, 510060, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.